STING Membrane Prevents Post-Surgery Tissue Adhesion and Tumor Recurrence of Colorectal Cancer.
Jianlin LiHaiwang YuYan KangKun NiuMing WangYitong JiangNi JiangZhenshan DingZhihua GanQingsong YuPublished in: Advanced materials (Deerfield Beach, Fla.) (2024)
Surgery is the standard treatment regimen for resectable colorectal cancer (CRC). However, it is very hard to completely remove all cancer cells in clinical practice, leading to the high recurrence rates of the disease. Moreover, the post-surgery tissue adhesion greatly prevents the possibility of reoperation, significantly limiting the long-term surviving of CRC patients. To overcome CRC recurrence and avoid the post-surgery tissue adhesion, this work develops a novel stimulator of interferon genes "STING" membrane based on the coaxial electrospinning technology and hyaluronic acid modification. A reactive oxygen species responsive prodrug of gambogic acid (GB) and a potent STING agonist (CDN) are coloaded in the core-shell structure of the membrane, which endows the loaded drug with sustained and sequential release patterns. The localized delivery of GB and CDN can selectively induce efficient immunogenic cell death of cancer cells and then evoke the systemic anticancer immunity by activating the Cyclic GMP-AMP (cGAMP) synthase/STING pathway. As-designed "STING" membrane not only safely prevents tumor recurrence through the synergistic chemoimmunotherapy but also efficiently avoids the post-surgery tissue adhesion, facilitating the clinical intervention of CRC.
Keyphrases
- minimally invasive
- coronary artery bypass
- cell death
- hyaluronic acid
- surgical site infection
- biofilm formation
- cancer therapy
- reactive oxygen species
- randomized controlled trial
- free survival
- clinical practice
- ejection fraction
- emergency department
- mouse model
- gene expression
- dendritic cells
- newly diagnosed
- percutaneous coronary intervention
- dna methylation
- immune response
- pseudomonas aeruginosa
- prognostic factors
- genome wide
- acute coronary syndrome
- escherichia coli
- rectal cancer
- anti inflammatory